New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
09:21 EDTEXASFDA says Exact Sciences colorectal cancer screening tool study met objectives
Exact Sciences' Deep-C study met the primary objectives with respect to both required sensitivity and specificity of the company's Cologuard test compared to colonoscopy, FDA staff wrote in briefing documents ahead of the March 27 meeting of the Molecular and Clinical Advisory Committee Panel. With respect to the secondary objectives, Cologuard sensitivity is higher than FIT for both CRC and AA, FDA staff noted. Cologuard is an in vitro diagnostic device designed to analyze patientsí stool for the presence of colorectal cancer. Reference Link
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:37 EDTEXASHigh option volume stocks
Subscribe for More Information
July 22, 2014
14:39 EDTEXASExact Sciences Cologuard to be approved in August or September, says Mizuho
Subscribe for More Information
07:37 EDTEXASExact Sciences reports Q2 EPS (24c), consensus (25c)
Exact reported total revenues of $0.0 million for the second quarter of 2014, compared to $1.0 million for the second quarter of 2013.
07:08 EDTEXASLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use